<SEC-DOCUMENT>0000950170-24-104550.txt : 20240909
<SEC-HEADER>0000950170-24-104550.hdr.sgml : 20240909
<ACCEPTANCE-DATETIME>20240909071614
ACCESSION NUMBER:		0000950170-24-104550
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20240909
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240909
DATE AS OF CHANGE:		20240909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		241285847

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tern-20240909.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-09T07:15:20.1629+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:tern="http://www.ternspharma.com/20240909" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c268a77c-7d7a-42cd-9d0f-a3aa2a68e6aa" name="dei:EntityCentralIndexKey" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce">0001831363</ix:nonNumeric><ix:nonNumeric id="F_14711f8e-01ab-49e3-9c6c-7d6568c5d589" name="dei:AmendmentFlag" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tern-20240909.xsd"/></ix:references><ix:resources><xbrli:context id="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-09</xbrli:startDate><xbrli:endDate>2024-09-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1dbcf14-3003-4c8c-b8a4-c6aff6ce0bea" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_ddf31814-f735-4571-9e21-8192c75e5cb7" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 09, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82399526-07bb-494a-9aa8-365cce96c7cb" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2e2b6c2d-d1a9-49d2-ad46-18a68a0e5466" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9de20e65-34c8-453f-927f-08b9c22f7a31" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39926</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9a6271e0-00dc-4e58-ac3a-b9bc2d34d828" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98-1448275</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_65c8cf6f-e1bb-4b82-b4e0-cb02fcab76d0" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1065 East Hillsdale Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1598dc80-df61-406a-bce0-a01ae1b2dd26" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d4409197-2ec2-4ba3-b91b-e2b1fd7393ae" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_11111b97-e2d8-4342-80a8-072dc797402c" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1d10ee26-e2ce-4c78-9d3f-f6b28cac1798" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94404</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_4c86dbb3-1c62-4e29-8f53-a5af071b345d" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_3ae234ba-4c24-4d25-9a2a-0427ad206110" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">525-5535</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_17260cc8-d9c8-4d96-be68-5c0f718e7c1e" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2dd71fb-7a7f-4d8f-86d9-d45e1a38a4ef" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb85245c-0881-4120-b245-7e7ebc35160f" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efcd068d-e01e-4f0d-a485-c7c878f7d85f" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d58c7c1-8f8b-4d0b-8fca-1c706e2a98e4" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_64861beb-643d-41d7-bedd-15896c262cda" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6fed7523-8058-4d53-b2a9-a885aa87fa5b" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7e313903-52b9-4fea-ab4c-6e8c530455d9" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_b41ad591-f83a-4d4b-a34a-bc006ee3ba4e" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_130c82fa-b3f8-4331-8575-3d3b407abd55" contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 9, 2024, Terns Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Terns&#8221;) issued a press release announcing positive top-line data from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 9, 2024, Terns announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled SAD/MAD trial to assess the safety, tolerability, PK and PD of TERN-601 QD in healthy adults with obesity or overweight. The clinical trial results showed TERN-601 was well tolerated and demonstrated dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses evaluated in the 28-day MAD study, with maximum placebo-adjusted mean weight loss of 4.9% (p&lt;0.0001) at the highest dose of 740 mg QD. Additionally, 67% of participants lost 5% or more of their baseline body weight at the top dose.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Terns believes these data support the potential of TERN-601 for the treatment of obesity as monotherapy or in combination with agents such as TERN-501, the Company&#8217;s internally discovered, clinical stage THR-&#946; agonist, or a GIPR modulator from the Company&#8217;s TERN-800 series. Terns anticipates advancing TERN-601 into Phase 2 clinical development in 2025. Terns believes it has successfully identified an optimal range of clinically active, well tolerated doses to take forward in Phase 2 clinical trials, with no new dose range exploration anticipated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#111111;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table 1: Mean Percent Weight Change from Baseline to Day 28</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.076%;"/>
    <td style="width:19.716%;"/>
    <td style="width:19.736%;"/>
    <td style="width:19.736%;"/>
    <td style="width:19.736%;"/>
   </tr>
   <tr style="height:37.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Placebo<br/>(N=9)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240 mg<br/>(N=9)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500 mg<br/>(N=9)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601<br/>740 mg<br/>(N=9)</span></p></td>
   </tr>
   <tr style="height:25.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">% weight change<br/>from baseline</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">-0.6%</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">-2.5%</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">-4.4%</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">-5.5%</span></p></td>
   </tr>
   <tr style="height:37.45pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% weight change<br/>placebo-adjusted<br/>(90% CI)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-1.9%</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-3.8%</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-4.9%</span></p></td>
   </tr>
   <tr style="height:25.55pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">Exploratory p-value<br/>vs. placebo</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">&lt;0.1</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">&lt;0.01</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#010101;white-space:pre-wrap;min-width:fit-content;">&lt;0.0001</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10.2pt;text-align:left;"><span style="color:#010101;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#111111;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERN-601 was well tolerated with no treatment-related dose interruptions, reductions or discontinuations at any dose,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> despite fast titration to high doses</span><span style="color:#111111;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The majority (&gt;95%) of treatment emergent adverse events (AEs) were mild. All gastrointestinal AEs were mild to moderate and consistent with the GLP-1R agonist class. Importantly, there were no clinically meaningful changes in liver enzymes, vital signs or electrocardiograms observed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The absence of treatment-related dose interruptions, reductions, or discontinuations with mostly mild AEs, despite aggressive titration to high doses in this 28-day study, indicates potential for further improved tolerability in subsequent studies with slower titration.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERN-601 has distinct properties that may be advantageous for an oral GLP-1R agonist. Its low solubility and high gut permeability may result in prolonged absorption allowing for sustained target coverage and a flat PK curve, while high drug levels in the gut wall may lead to robust GLP-1R activation in the gut triggering satiety centers in the brain. Additionally, TERN-601 has a low free fraction in circulation which, combined with the flat PK curve, may be allowing TERN-601 to be well tolerated when administered at high doses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#010101;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table 2: Treatment Emergent Adverse Events by Maximum Severity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:1.204%;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.415%;"/>
    <td style="width:14.377%;"/>
    <td style="width:19.736%;"/>
    <td style="width:19.736%;"/>
    <td style="width:19.736%;"/>
   </tr>
   <tr style="height:37.85pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Placebo<br/>(N=9)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">240 mg<br/>(N=10)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">500 mg<br/>(N=9)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN-601<br/>740 mg<br/>(N=9)</span></p></td>
   </tr>
   <tr style="height:2.5pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Grade 1 (Mild)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 (55.6%)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 (50%)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (100%)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (33.3%)</span></p></td>
   </tr>
   <tr style="height:8.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Grade 2 (Moderate)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (10%)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6 (66.7%)</span></p></td>
   </tr>
   <tr style="height:7.65pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Grade &#8805;3 (Severe)</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:4.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Serious Adverse Events</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company&#8217;s small-molecule product candidates; the potential for the mechanisms of action of the Company&#8217;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#8217;s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company&#8217;s clinical trials; the Company&#8217;s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company&#8217;s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company&#8217;s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the Company&#8217;s plans and expectations around the addition of key personnel; and the Company&#8217;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company&#8217;s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#8217;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#8217;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company&#8217;s actual results, please refer to the risk factors identified in the Company&#8217;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.5%;"/>
    <td style="width:2.5%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tern-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release issued by Terns Pharmaceuticals, Inc. on September 9, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September 9, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Elona Kogan</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elona Kogan<br/>Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> Distinct drug properties support potential to be a leading GLP-1R agonist</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Plans to initiate Phase 2 clinical trial in 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Company to host conference call today at 8:00 am ET</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">FOSTER CITY, Calif., September 9, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (&#x201c;Terns&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The clinical trial results showed TERN-601 was well tolerated and demonstrated dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses evaluated in the 28-day MAD study, with maximum placebo-adjusted mean weight loss of 4.9% (p&lt;0.0001) at the highest dose of 740 mg QD. Additionally, 67% of participants lost 5% or more of their baseline body weight at the top dose.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;These compelling results underscore TERN-601&#x2019;s potential to be a class-leading GLP-1R agonist based on its composite profile of initial indications of efficacy, tolerability and manufacturing scalability,&#x201d; said Amy Burroughs, chief executive officer of Terns. &#x201c;These data validate the potential of TERN-601 for the treatment of obesity as monotherapy or in combination with agents such as TERN-501, our internally discovered, clinical stage THR-&#x3b2; agonist, or a GIPR modulator from our TERN-800 series. With operational preparations well underway, we look forward to swiftly advancing this promising product candidate into Phase 2 clinical development in 2025.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are delighted to demonstrate potent GLP-1R agonism with TERN-601 as its distinct drug properties allowed for sustained target coverage with once-daily dosing and the evaluation of doses up to 740 mg, while being tolerable,&#x201d; noted Emil Kuriakose, chief medical officer of Terns. &#x201c;Importantly, we believe we have successfully identified an optimal range of clinically active, well tolerated doses to take forward in Phase 2 clinical trials, with no new dose range exploration anticipated.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;" />
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Table 1: Mean Percent Weight Change from Baseline to Day 28</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.076%;"></td>
    <td style="width:19.716%;"></td>
    <td style="width:19.736%;"></td>
    <td style="width:19.736%;"></td>
    <td style="width:19.736%;"></td>
   </tr>
   <tr style="height:38.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Placebo<br />(N=9)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">240 mg<br />(N=9)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">500 mg<br />(N=9)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601<br />740 mg<br />(N=9)</font></p></td>
   </tr>
   <tr style="height:25.2pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">% weight change<br />from baseline</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-0.6%</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-2.5%</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-4.4%</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-5.5%</font></p></td>
   </tr>
   <tr style="height:37.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">% weight change<br />placebo-adjusted<br />(90% CI)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-1.9%</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-3.8%</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-4.9%</font></p></td>
   </tr>
   <tr style="height:25.2pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Exploratory p-value<br />vs. placebo</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">-</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&lt;0.1</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&lt;0.01</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#010101;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&lt;0.0001</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10.2pt;text-align:left;"><font style="color:#010101;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br /></font><font style="color:#111111;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601 was well tolerated with no treatment-related dose interruptions, reductions or discontinuations at any dose,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> despite fast titration to high doses</font><font style="color:#111111;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.  The majority (&gt;95%) of treatment emergent AEs were mild. All gastrointestinal events were mild to moderate and consistent with the GLP-1R agonist class. Importantly, there were no clinically meaningful changes in liver enzymes, vital signs or electrocardiograms observed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> The absence of treatment-related dose interruptions, reductions, or discontinuations with mostly mild AEs, despite aggressive titration to high doses in this 28-day study, indicates potential for further improved tolerability in subsequent studies with slower titration.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601 has distinct properties that may be advantageous for an oral GLP-1R agonist.  Its low solubility and high gut permeability may result in prolonged absorption allowing for sustained target coverage and a flat PK curve, while high drug levels in the gut wall may lead to robust GLP-1R activation in the gut triggering satiety centers in the brain. Additionally, TERN-601 has a low free fraction in circulation which, combined with the flat PK curve, may be allowing TERN-601 to be well tolerated when administered at high doses.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#010101;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Table 2: Treatment Emergent Adverse Events by Maximum Severity</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.415%;"></td>
    <td style="width:14.377%;"></td>
    <td style="width:19.736%;"></td>
    <td style="width:19.736%;"></td>
    <td style="width:19.736%;"></td>
   </tr>
   <tr style="height:38.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Placebo<br />(N=9)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">240 mg<br />(N=10)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">500 mg<br />(N=9)</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-601<br />740 mg<br />(N=9)</font></p></td>
   </tr>
   <tr style="height:2.15pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Grade 1 (Mild)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">5 (55.6%)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">5 (50%)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">9 (100%)</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">3 (33.3%)</font></p></td>
   </tr>
   <tr style="height:7.9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Grade 2 (Moderate)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1 (10%)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">6 (66.7%)</font></p></td>
   </tr>
   <tr style="height:7.9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Grade &#x2265;3 (Severe)</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
   </tr>
   <tr style="height:5.05pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:1pt solid #000000;border-left:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;&#160;Serious Adverse Events</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:1pt solid #000000;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.104in;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">0</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br /></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns plans to submit data from this informative clinical trial for presentation at an upcoming scientific conference.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call and Webcast</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns will host a conference call for investors today, September 9, 2024, beginning at 8:00 a.m. ET. The live webcast of the conference call can be accessed </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. A replay of the call will also be available on the Events page of the Investor Relations section of the Terns website for 30 days.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;" />
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About the TERN-601 Phase 1 Trial </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br />The Phase 1 trial was a randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 in healthy adults with obesity or overweight. The trial consisted of two parts.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Part 1 (SAD) was a single ascending dose study that evaluated five TERN-601 dose levels in healthy participants with a Body Mass Index (BMI) of &#x2265; 25 kg/m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> and &lt; 40 kg/m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. The starting TERN-601 dose was 30 mg, with subsequent dose levels based on review of emerging safety and PK data from prior cohorts.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In Part 2 (MAD) of the trial, obese and overweight healthy adults were enrolled in cohorts that included titration of TERN-601 administered for 28 days at doses selected based on data from Part 1 (SAD). Part 2 included healthy participants with a BMI of &#x2265; 27 kg/m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> to &lt; 40 kg/m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br />The primary endpoint of the trial was to evaluate safety and tolerability of TERN-601 administered once-daily for 28 days. Secondary endpoints included PK, efficacy as measured by body weight loss following 28 days of treatment with TERN-601, and other exploratory markers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About TERN-601</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br />TERN-601 is an oral, small-molecule glucagon-like peptide-1 receptor agonist, or GLP-1R agonist, internally discovered at Terns for development in obesity. TERN-601 was designed through internal structure-based drug discovery efforts employing Terns&#x2019; proprietary three-dimensional QSAR model of the receptor. The ligands were further optimized based on in vitro activity, metabolic stability, and pharmacokinetic parameters. This process led to the selection of TERN-601, a potent GLP-1R agonist biased towards cAMP generation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Terns Pharmaceuticals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity. Terns&#x2019; pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-&#x3b2; agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.ternspharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;" />
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company&#x2019;s small-molecule product candidates; the potential for the mechanisms of action of the Company&#x2019;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#x2019;s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company&#x2019;s clinical trials; the Company&#x2019;s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company&#x2019;s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company&#x2019;s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the Company&#x2019;s plans and expectations around the addition of key personnel; and the Company&#x2019;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company&#x2019;s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#x2019;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#x2019;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company&#x2019;s actual results, please refer to the risk factors identified in the Company&#x2019;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Contacts for Terns</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Justin Ng</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">investors@ternspharma.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Media</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Jenna Urban</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Berry &amp; Company Public Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">media@ternspharma.com</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="page-break-after:always;" />
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tern-20240909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-09T07:15:20.5554+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ternspharma.com/20240909" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tern="http://www.ternspharma.com/20240909" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20240909.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>5
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139653484682368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  09,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>6
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ !CHI63JJHN=  0  / (   \
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    (  8Z*5F&'1AR[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  8Z
M*5F97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ !CHI63%MGH6\!   D!(  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  8Z
M*5F?H!OPL0(  .(,   -              "  ?\,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ !CHI69>*NQS     $P(   L              ( !VP\
M %]R96QS+RYR96QS4$L! A0#%     @ !CHI63JJHN=  0  / (   \
M         ( !Q!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  8Z*5DD
M'INBK0   /@!   :              "  3$2  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    (  8Z*5EED'F2&0$  ,\#   3
M      "  183  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' & 4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tern-20240909.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tern-20240909.htm">tern-20240909.htm</File>
    <File>tern-20240909.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tern-20240909.htm": {
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20240909",
   "dts": {
    "inline": {
     "local": [
      "tern-20240909.htm"
     ]
    },
    "schema": {
     "local": [
      "tern-20240909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_aa4f164a-fd98-4e00-9ed5-4545289d04ce",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20240909.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aa4f164a-fd98-4e00-9ed5-4545289d04ce",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20240909.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ternspharma.com/20240909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-24-104550-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-104550-xbrl.zip
M4$L#!!0    (  8Z*5D4'-J!^"   (P4 0 1    =&5R;BTR,#(T,#DP.2YH
M=&WM/6MSVSB2W_=7X#*7&:?.D/F42#G)EL=V9GR3.%[;6[MU7[9  I2XH4@-
M0=K6_OKK!DB])=NR%,NQYJXV%@GBT>@7&OUX_]>[7D)N1"[C+/WPB]DP?B$B
M#3,>IYT/OQQ='9^=_?+7CW]Y_U^4DI-/9^?D7-R2H["(;\1)+,,DDV4NR-[5
MEW?D+$WB5)!__GKYF9QD8=D3:4$HZ19%OWUP<'M[V^!1G,HL*0L82S;"K'=
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MSE(N[OX0@VJ)=\6EB&#Q_V+,B<RFPVC$?8\ZPC"H+[A+'==Q+0_Z=P![/AJ
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M)6>%),< 5)C\NZ<?)!ZK-^^XY!9SR6W4;JV1<CM']5WR;OF'WI*7COF=]6D
M N[#AS?VF^?7K1>RN/DRRA)6T PM3KG)?)!1W**,.TUJ>JSI,4.X3K.Y'AD%
MC#_+08%6=V]7!6#6<5:F13XXSOBDTHKW@7A;4(A^GMU@/QO55D]$PFY9+AZA
MHV[',>J16^US81FBZ5+;"6';7#NBOM6*J.$%?FA948OA;>HZMOI3G @8&PX
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MP+E)9OF# -28#]+OD,3?-!K6PT/#-NMAH 3'DMB2!WK!K.P LL31LO8:&OJ
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M!5Q=#V_!+7P" \-!C_ *V89%;)="\';TY1WX]OO##1@9<[C0P14QW 7$#E#
MW'&6/55]>GIJFU.$;6*Y#JO.;AMDH0)%"< O*=3Y>7"E.Q#TNEKW@Z*=L9^Q
M]K'7.64GVJ>GIQ]^T;2>IL6*D>4S1;.Y ]X:[P OQ>K&&%K6,[A&6,<&TBTP
M$I6^!T-LM,' LL #+V6#!VA#^@C-MH^YLLV>[6MP=#J#SJV^@/92-V"_%5/B
M0(KMY5RG"]W3P2O6SK2S%M =AZ*)Z\!K0A=7<*J[EM-ON?@_5[?0%$&3W6(+
M\GN3"(A=9FV"[1[$[J(;UKF:4*M-Z(Q7I*EPY4!LHXD%%1X&J7?G;*7+&] O
MSG0D"#^=!,6UCOKMRXW?3"+80OA'(CI6G7:B\LL3W88BW+65F:XOPQ)3W9YX
MT<$%[VZ(8!.BI H;&NT9>539A40@OV@Z,L7:J>I?%*'\[I=LC@@;%2ADW=)A
M7254N,K<D>#^=<[.SE3O:NOB)P"\[H(62T(=X/>:&V)XC5%0&?]+$34J_)32
MZ2HGG38#:P$L[6\Y=-7M2(B&W8A$V"LV)2%:E==^FE>OM!N4JM'.ZW#\0.$'
MA75FNNG+*I6."15:CBW.%%*0#ZF(@HXQ<;QZ^2EQ<KE$>$K\,^P<;Z$>)18<
M/R\AX =?'X:EQHWJZ"N"R>)9Y:54,9N+WP-L?L8.<IZ'K#I6EO-H <1FG <6
M_KU4N& I>)J0/1R0IZBC\7_LT1%[BH2'# SX:" &=ZZF05+PK@W-.WSA'2\I
MF_.Q?_MNV(F@<!!24-#0+<.U7EXNHI5;+#@I6BO9AF*H>;?8"N:>=",_P&GU
M;>Q-?;TYA=-^BP,K HUWY#?E6S\ <IC4?LMF \H*YI&$;'T"+7['@FC.LV!"
M\F1X4[- 1PXO$,(D:_4>HB9[X$;5AA43(Q%J\3%.:%)^^3GF#?OC^R5AZZS!
MQ':H;C@"R:/6;V6OJ_60&K &,KVUB*7/)*22UVLB=<GZRH"M!B^)"64W*GZY
M)DJB+]]#B@CKSB9?I$JXR>-J)LGGCP)NWN6:*/D#?V":;,:U@U]L),*.A%]^
M;,-DNR\@VVV$+!\2=W1,GO ZJK'()HC>$[9PM?Y&RYRQ71#<!-T16R/ .WI/
MR2/RWPX*":?#:Z5\R88VU:TA>Z2M_H3/N5S3<;62_,S>56<(S_Z@Y,F97Y+%
M4L?Y5.71]1)>C:G.7K7YHL6?U//99D-KI7J-+'CK+B:0YE*,A=1*;8@-0MD[
MD[?V\T;))7%9-WPNG :*2]4L(%RZ<M<&TALXTZT[^@!GR&;K8&ARFZA 2:GB
MM4KRZV8]UBFDG@JKE>)87PU--EVA*?+?L==T[[SXFDAS)\"ZGQ.</PPS(351
MNZ=L["S8ZL_PG,>A;;N0COGK#[V;3J54UQ9IAOJ+2#= =P0-E[*^V.E.QOSU
M4T(R$U(SM<\K8Z[C&<P9]]*PNB@2"QGL"8IG7]AT3Y%NR0AF@VJBQQ[P_*.1
MT?-B0F3,DM=K(O47:RP'8M[O71Q,?+:$G#Q.1I*7X48X.^*? T&L?!TEO1.V
MVB4NE:Z($S[&=VL2WJ=2[@W':5UX&. ?@?)O8(YY5U^;;\+BV)!OB $X2)5L
MX^;'IC>76Z<< W"0*LE*W9 -68?^KP\&&)KW26$=_+ECLBUMCE$EUUSW9$/B
M@<4>(+T7!X!C@CO<B)9N%5K&3Z0V+9'[\DI*O+%,*."0M:E(^#*O),3'! RT
M\EFIR+)Y)34>*F\7@5N]GI2MLYV0  QX:(#!5<]?ZO5LIT)  A\3!* U:,DX
M05L*68$(,'@ 5J\B,HNV8\]Q@ ]4/>E"SV@['0GHV!@/*JAIWBIG)6VK-*SC
M/?!K 5XU7&Y4$> U5:\XZ4!MIRS"JHE\CB6UG0H&"I*H-8ROM'6UH00/!G@X
M-9!>9V)M*(+!*D8,%_C P$<&'G2-LBH05)>2M!>V(7^O+"!3T.F^G;P# K4.
MYG&;;$/V @H(K,HGIZR%MBGU$ @(I"IY)PRV3?N*CP%\D"K92AVW#5D'6" )
M5H+]@"8M1YT:HGIVN(9!$*$:A$T,2T?QR03%IY0L9+E+HCJ29PCF>8YU4)5F
M/ FJ62^P2:JR/*CPIJ9]P":)%F9'"<;Y9N N4(_G3*49A_9?DT379E()UL5&
MX"Y*Z):5T-TM"=FL*ZF E.FW,_2EN5A2!5G#;V=$Y&1H267(O+[FA>3D;245
MR-R]YJD79G,E!>3;>SL@(S?'*Z5!;NLU+R";^94DGG+RFB=<*A\LJ6&]L;<+
MLEZ2)9;65]K7:UZH/'<L*4ABVS5/?$U&65)!D7?7I)2\/#/!7NK4-4FX;/:9
M$%#*M=LA0>6E[)*(O$PU05UJS>T"85G^6IITQI5KE'AN5EM(6^['-4E:FNLF
M^&9]N":I%F; "<KY9EQ\WV',3V-OG#_2.Q+3.T?S?+P*]EP&FQG3#))FY'%/
MXW%/XW%/8[64CGL::R%[W--XW--XW--8">'CGL97H';<TWC<TWC<TR@+.>YI
M/.YI/.YI/.YIW(+4J^]IC-LFKV))+77*\!1CCJQP^50R(2IE4!#*QG._U=&T
MCL;__\8E6V;QOMIOL9<TUV9DR)+3EG>)71*6-#E"79V3/=>5XY1$#=<]$(&^
MRQ+ITO9<5X%5$XD\.U"1W83(S@&)C%M#T2QS4)TU92I%*O=]JBGVHB*=^_XL
MS#&PHA'YX2 $YIA?D<S3PY IL<Q"C=W#F'GB7EO4?K\>A+8U9ETD]^.!R"UG
M[473[6$,T[3_%[7KOK^"K#$/(Z&_[;G0K.$8==)]?V2N=RPCK?O^5E)D<48J
M][VW9IW1:%6P[RM8N;4:ZCO9]]$H\V6CGKGO"X&4K1MURWU_@<RQAJ.6>\F*
M-<CW2R?5B0"1#HC\KU_P3Y^KJ>_:"$[$OI'#/^-_/\C%_U!+ P04    "  &
M.BE9&.9$&H87  #3NP  #P   '1E<FXM97@Y.5\Q+FAT;>U=ZW?;-K+_OG\%
M;GO2=<Z1&$E^Q5*VYSJ.M^M-D[IV]N3>CQ )2:A)@@5(R^I?OS,#@*(DVGE9
MEF(S/:>V21"/>?QF\!C,JTF>Q#__C;V:"![!3_8JEWDL?C[]O_;14=!]]<+^
M"05>N!*OABJ:,9//8O&/'Q*NQS+M,U[DZG]DDBF=\S0?9#R*9#KNLY?9S> '
MJC:2U_XC][:=JZS?"?9E.OBK+=-(W/3;NX-$INV)D.-)WN_"FTP9F4N5]K6(
M>2ZOQ6"H;MI&_H75#Y6.A&[#$VCD5>;K'ZDTQR*BW^UD^<#VT;8VH'<CGLAX
MUO\@$V'8>S%E%RKAJ2\X5'FN$BB;BYN\S6,YAM:Q0]@(?N_;"56L=/_'#OT;
M3"<R%VV3\5#T,RW:4\TSV]S4#F>HXFBPU+<[NP-]F<HHG_1',F^'4%*DV(?3
MFXD<RIQ9_F -/[]ZD:UW_+$8K0S_]@%_V_A^^K%[T!D\C9&] +4@];CG(;Z$
M3RN##*%]H>]9?KM+5/C["30VU/+O+<-3TS9"R]&MI/@@=&K8^83K!!HL<AGR
MV+#C-%5%&L+ SDGOKP46,8)UV4DL4RS$/F@)_[\0IHASPZ8RG[ /IQ?OVP>=
M+OL-OFV_X= ;]IN&4K_\>M[N7K#CL4JER=E(:99/!%0A>)Y 1Y@:L=^& IJ:
M5;BR[?SX O+;\EA]7^;P/KR5(9<YP*LA/@#U#/12CN /Z%TB>,JL#+!8&<.*
MC.6*[0?[SYBZ%IKU7K*(SPS;V0N.GK$LAAX/%>/1'X7)1?3\J5/VHXAC&%8L
M- =R6(E-%<N]$+;)M,&;2(&D2^R_+C(T>J;%M(B*T/T.TAM)@Q7+M.#TD(EK
MD=HJ81#2U0$V6]/[ITYZ]@9%.@US%NEBS#*M,J%S"6,R18;."LL4%D5$ 9$>
M"L99#&X..!<>.[C%#D_)[1G:4^?M>0Q?(=? +@ #<V\J>BSTIB(G4R%3UNOT
M]I\ZO4Y4DO%TAA2;*#"&\&8DM "+R1#SX3F ..,Y>]GO=!A/V.F'!R59G2.V
M!H+=1IY__G8);@0[.?OP_RV&'XZ"%KL462Z2(=BXHQ8*T1[;^>77WUZ?LO>G
M'R\_GEV</F?M-JOU95KL+ T#MO/3CS>]3C<<4"'[1S1@SA'Q+QUO_.OG;.<]
M-Q'_LT^NS?,6P)(7:F V'PLVE"I;:!#X:?D;@4F(5880QAEBW$C%4J&G8Q+@
M<SL!2Q06L4 T1-L"W$\C&8$"D3;!W$P+,/)(+548M#@"U K&XP3$N6@1R[R+
M!HQO0^\$> $Y9R.M$B9S4WIN&NI7"7 H:H%Y*H:Q: ^A./SE7 7B@E9Q#)4:
MZ#?T#3YA"3AX,H/2W( Z$2:3==NY/'Y#!=X=OWGN=!P[;@SV&\EJ^$CD,^PQ
M&MVAC"7^Y>BEKJ"K0#+P5\[?/J>*_)MHEH+DT!NH&2A6.I;8<,04NI<1N9<[
MOT,)0!:8%,?Y!,@2S=U193U*9#+Z1]9U"A[(@FR'O=BP,G\ (5BR MI-&,Q$
M38&5)6>G'+@F"/^\AX8B$8D$W*M<EXY9.Q(92"'4WX(!W>8K>XGVSN^J\\Q#
M33^PQ8D6@BI'/X['!34&0H4RW'O91G4#&8?FB@CDEV0KX3<R*9+/: C$E_SQ
MG>RG.!]T B!Z]SGB.]8^@7("C  I%)0\W.NP9,Q^?Q.PXRBB%1<<6XL='#[#
M]QD'MRF4 #! PAC-!SK_FB5*T_=0I]1L" I/0$!+1*XSKD40*&HM>$IR6((_
M$%L00H.D(9!Y:2Q HC2X]$!%+Y'VFZ.!J?%-PQA0KEWOH1+U$:,(?+$MQ&>"
M^9&,B4O64T*/* )QM1,(>"Q&*+WA$F!:#.9I,>)A7FALT(# >S@M39GA,.TX
M3F;L=:&U*L83,!7A1 JH]P8,#5D(A2V %45(13L8L$7*D.$ #2 S1.(R'WL5
MAOT$/J].X#W<@B*#SBIX#RPD] 55 CH,94ICM0H$QA-EV!3A!+^@JO<[79A=
M%=I.ODCR[4P+T!NM5@DEUO9^^-=%&_J_.^P-//%I<L;9+V?G%] )L 4\AP=D
M"K%>:N4EN%4H+@*&_Y'L1";L- UJ!M$#'7,\(3PBT9AR5'P!*J>N</13KB.4
M!C.5HSQ&LW/-TQ!YDT^D05XG$DWHJG''L:E5%]EY"T1+YR@'GK7KU=1/KL)M
M0$\_@I*!*D: 8@!=@DA=L01.*A<5+UE:@P*A0@6,;IMY@G21!4)9-H#='  3
M&@+:"'3*0>10QJPC,?<W #K)HP.=1 5PY@*E&C3 FA"[+&.1'(1F@DH_%"0;
M5JUC,==:T!-H]11(Q=Z"<O,KJ,+K;2(BDHW;M?;,K_3'5CR'0# 0)/QUPN$G
M:%<(SMBH0$V2:#3!0))E!:'/98+VF*=C B4OBBC-(:)%:]D>V^'!V')^)4HM
M &FMG_"95KG&DH+LD8FSK8F;#$3*D@TZ3P8-&M@6@7^P96>_'T/F!/=CQJ*=
MJDCX;Z!?E>V:RN;,*!8W[4AJ04M2?=#0(DD'(.K@CLSZ^'9Y_P:]$SF:^9JI
M3!O\J)J-G1_<<OA\47RBYUM&T,4AH/Y5FX\ H_L\!F@T@Q_8B\>ZN_0XME<V
M/+1U[:]\MO'JXG_UQHMJB$3H$*E/!A_=Y_N;!B'FLVZ?O</)P;G0N"S%/EJ_
M_&1"F$@^RFOON /(OH%91^_EEMC^.\BWKHEQ3D1S_7 8@$TC)$"_\6T;T$X5
M &;R1D0#6^G10=!Y-G#EH?LQSXSH&^O5";L)#I67B'8-?IIUI?N^M"L$I:)2
M4ZCN7C?H'!X\(X3,HUL*=8^"P^[G%-I=5R'X12\/TX'M[LN@NP]<F@)]+([W
M+9KC@WK^KA+#$=<!>P;"HF#&X&FN+:K[Q\P[CNXU2MG"9]Y.N!?=SAX8A&MT
MTG"5S8HF-#4HS0!)[FK]M]B&[A9XQM^J#K7L_SHNW!>U:RBS3NI_VSK^U]#_
MW"[LO!IJ<&UVWO_CZ'G#D(TRQ$_L/N4Q?;\C[-&4L9&X;>''XY>X_<X:)&X=
MQOWIR!KQXO!SD. .-Z^W'_2 %$,>7HVU@@E-V_5]1/_NQ?U[@G[>IV9!7\/X
M9WY_)J1YH.4Y30;]+LYGZN23@OMU<*+="0Z>-<1^(&+W@OV&V ]%[+U@[\N(
M_>AM^%K(O'^+3-^U(',8[-W7@LP3M,CK<,5J+?+R.0_GFQUUGK&3L\]UF]<-
M9(^,$>TM(>M6 ==:"-T-CAIC_%#$W@U>-L9X_63>NT6FG\2TN5K#(YLPG[K#
M(TK/6-;&\S?.1%^;P!_'W B6/6*:;\825PFZ57BU#A+;P\'=AM /0^C.EU'Z
M?A'YJ="X4T]E;X'A)Y[B6,?!EFZ'+/GVG&ZQ)NJ.V),N_5MS.,8=P19?&PY;
M&PW+<T8A4'B8==/Q-I$P&9Z_'W&3SR-R*?P.5-L>:MTP7P+&,%(FX7\HC2?H
M=WX:YX.C_6<4^S0_8R\2H?'4/#L^1?9I^$+&4<".@9%C&)U6R"4\[LQC"DC.
M*\5PP(F*B-MT?!F:-]+0.6KB/1YG7HIDH'.I 5LX98S'^H6M%J2E<F@8 U\
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M6)&%*K$I,*2]S3ZL)-#:]!'MAS]@O*T2O(Y4I2?S1&DG&)R @0T?Q3#D\ZR
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MR^*Q0"IB(!W]FW\!+TU!2D:91*2YLA1=[#&1DT $H+(PPMK(,"\JTP5O%R7
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M2P$"% ,4    "  &.BE93%]@'/P(  !E:0  $0              @ $G(0
M=&5R;BTR,#(T,#DP.2YX<V102P$"% ,4    "  &.BE9&.9$&H87  #3NP
M#P              @ %2*@  =&5R;BUE>#DY7S$N:'1M4$L%!@     #  ,
*NP    5"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tern-20240909_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20240909.xsd" xlink:type="simple"/>
    <context id="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2024-09-09</startDate>
            <endDate>2024-09-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_c268a77c-7d7a-42cd-9d0f-a3aa2a68e6aa">0001831363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_14711f8e-01ab-49e3-9c6c-7d6568c5d589">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_d1dbcf14-3003-4c8c-b8a4-c6aff6ce0bea">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_ddf31814-f735-4571-9e21-8192c75e5cb7">2024-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_82399526-07bb-494a-9aa8-365cce96c7cb">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_2e2b6c2d-d1a9-49d2-ad46-18a68a0e5466">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_9de20e65-34c8-453f-927f-08b9c22f7a31">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_9a6271e0-00dc-4e58-ac3a-b9bc2d34d828">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_65c8cf6f-e1bb-4b82-b4e0-cb02fcab76d0">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_1598dc80-df61-406a-bce0-a01ae1b2dd26">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_d4409197-2ec2-4ba3-b91b-e2b1fd7393ae">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_11111b97-e2d8-4342-80a8-072dc797402c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_1d10ee26-e2ce-4c78-9d3f-f6b28cac1798">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_4c86dbb3-1c62-4e29-8f53-a5af071b345d">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_3ae234ba-4c24-4d25-9a2a-0427ad206110">525-5535</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_17260cc8-d9c8-4d96-be68-5c0f718e7c1e">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_f2dd71fb-7a7f-4d8f-86d9-d45e1a38a4ef">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_fb85245c-0881-4120-b245-7e7ebc35160f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_efcd068d-e01e-4f0d-a485-c7c878f7d85f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_1d58c7c1-8f8b-4d0b-8fca-1c706e2a98e4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_64861beb-643d-41d7-bedd-15896c262cda">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_6fed7523-8058-4d53-b2a9-a885aa87fa5b">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_7e313903-52b9-4fea-ab4c-6e8c530455d9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_b41ad591-f83a-4d4b-a34a-bc006ee3ba4e">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_aa4f164a-fd98-4e00-9ed5-4545289d04ce"
      id="F_130c82fa-b3f8-4331-8575-3d3b407abd55">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
